{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:01:44Z","timestamp":1792026104985,"version":"4.4.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary aldosteronism (PA) is a common form of endocrine hypertension previously believed to account for less than 1% of hypertensive patients. Hypokalemia was considered a prerequisite for pursuing diagnostic tests for PA. Recent studies applying the plasma aldosterone\/plasma renin activity ratio (ARR) as a screening test have reported a higher prevalence. This study is a retrospective evaluation of the diagnosis of PA from clinical centers in five continents before and after the widespread use of the ARR as a screening test. The application of this strategy to a greater number of hypertensives led to a 5- to 15-fold increase in the identification of patients affected by PA. Only a small proportion of patients (between 9 and 37%) were hypokalemic. The annual detection rate of aldosterone-producing adenoma (APA) increased in all centers (by 1.3\u20136.3 times) after the wide application of ARR. Aldosterone-producing adenomas constituted a much higher proportion of patients with PA in the four centers that employed adrenal venous sampling (28\u201350%) than in the center that did not (9%). In conclusion, the wide use of the ARR as a screening test in hypertensive patients led to a marked increase in the detection rate of PA.<\/jats:p>","DOI":"10.1210\/jc.2003-031337","type":"journal-article","created":{"date-parts":[[2004,3,4]],"date-time":"2004-03-04T20:53:04Z","timestamp":1078433584000},"page":"1045-1050","source":"Crossref","is-referenced-by-count":802,"title":["Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents"],"prefix":"10.1210","volume":"89","author":[{"given":"Paolo","family":"Mulatero","sequence":"first","affiliation":[{"name":"Hypertension Unit (P.M., F.V.), Department of Medicine and Experimental Oncology, University of Torino, 10133 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stowasser","sequence":"additional","affiliation":[{"name":"Hypertension Unit (M.S., R.D.G.), Department of Medicine, University of Queensland, Princess Alexandra and Greenslopes Hospitals, Brisbane, Australia 4212"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keh-Chuan","family":"Loh","sequence":"additional","affiliation":[{"name":"Endocrine Unit (K.-C. L.), Tan Tock Seng Hospital, Singapore, Republic of Singapore 308433"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Fardella","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.E.F., L.M.), Faculty of Medicine, P. Universidad Cato\u0300lica de Chile, 114D Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Hypertension Unit (M.S., R.D.G.), Department of Medicine, University of Queensland, Princess Alexandra and Greenslopes Hospitals, Brisbane, Australia 4212"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Mosso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (C.E.F., L.M.), Faculty of Medicine, P. Universidad Cato\u0300lica de Chile, 114D Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso E.","family":"Gomez-Sanchez","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (C.E.G.-S.), University of Mississippi Medical Center, Jackson, Mississippi 39216"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Veglio","sequence":"additional","affiliation":[{"name":"Hypertension Unit (P.M., F.V.), Department of Medicine and Experimental Oncology, University of Torino, 10133 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William F.","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (W.F.Y.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616144321800_R1","article-title":"Clinical hypertension","author":"Kaplan","year":"1994"},{"key":"2020071616144321800_R2","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199812173392507","article-title":"Primary aldosteronism.","volume":"339","author":"Ganguly","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071616144321800_R3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","article-title":"Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers.","volume":"20","author":"Gordon","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2020071616144321800_R4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","article-title":"High incidence of primary aldosteronism in 199 patients referred with hypertension.","volume":"21","author":"Gordon","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2020071616144321800_R5","first-page":"2854","article-title":"Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.","volume":"85","author":"Loh","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144321800_R6","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144321800_R7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism.","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"2020071616144321800_R8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(00)04223-9","article-title":"Cautions over the current epidemic of primary aldosteronism.","volume":"357","author":"Kaplan","year":"2001","journal-title":"Lancet"},{"key":"2020071616144321800_R9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","article-title":"Potentially high prevalence of primary aldosteronism in a primary-care population.","volume":"353","author":"Lim","year":"1999","journal-title":"Lancet"},{"key":"2020071616144321800_R10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.HYP.6.5.717","article-title":"Further evaluation of saline infusion for the diagnosis of primary aldosteronism.","volume":"6","author":"Holland","year":"1984","journal-title":"Hypertension"},{"key":"2020071616144321800_R11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0039-6060(96)80033-X","article-title":"Primary aldosteronism: adrenal venous sampling.","volume":"120","author":"Young Jr","year":"1996","journal-title":"Surgery"},{"key":"2020071616144321800_R12","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1210\/jcem.83.7.4946","article-title":"Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene.","volume":"83","author":"Mulatero","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144321800_R13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/bbrc.1995.1225","article-title":"A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension.","volume":"207","author":"Jonsson","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071616144321800_R14","first-page":"3996","article-title":"Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol.","volume":"83","author":"Mulatero","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144321800_R15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1749-6632.2002.tb04413.x","article-title":"Primary aldosteronism: management issues.","volume":"970","author":"Young Jr","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2020071616144321800_R16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","article-title":"Primary aldosteronism: factors associated with normalization of blood pressure after surgery.","volume":"135","author":"Sawka","year":"2001","journal-title":"Ann Intern Med"},{"key":"2020071616144321800_R17","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart.","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"2020071616144321800_R18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1006\/jmcc.2002.2088","article-title":"Molecular mechanisms of myocardial remodeling. The role of aldosterone.","volume":"34","author":"Delcayre","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"2020071616144321800_R19","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071616144321800_R20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","article-title":"Aldosterone-induced inflammation in the rat heart: role of oxidative stress.","volume":"161","author":"Sun","year":"2002","journal-title":"Am J Pathol"},{"key":"2020071616144321800_R21","first-page":"E657","article-title":"Determinants of cardiac fibrosis in experimental hypermineralocorticoid states","volume":"269","author":"Young","year":"1995","journal-title":"Am J Physiol"},{"key":"2020071616144321800_R22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system.","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2020071616144321800_R23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma.","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"2020071616144321800_R24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0895-7061(02)03199-0","article-title":"Aldosterone-induced cardiac damage: focus on blood pressure independent effects.","volume":"16","author":"Schmidt","year":"2003","journal-title":"Am J Hypertens"},{"key":"2020071616144321800_R25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071616144321800_R26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071616144321800_R27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0895-7061(01)02261-0","article-title":"Abstract, closing summary, and table of contents for Laragh\u2019s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension.","volume":"14","author":"Laragh","year":"2001","journal-title":"Am J Hypertens"},{"key":"2020071616144321800_R28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1365-2168.2002.02261.x","article-title":"Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism.","volume":"89","author":"Sywak","year":"2002","journal-title":"Br J Surg"},{"key":"2020071616144321800_R29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0895-7061(98)00080-6","article-title":"Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension.","volume":"11","author":"Blumenfeld","year":"1998","journal-title":"Am J Hypertens"},{"key":"2020071616144321800_R30","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"2020071616144321800_R31","first-page":"S103","article-title":"Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension","volume":"5","author":"Gordon","year":"1987","journal-title":"J Hypertens Suppl"},{"key":"2020071616144321800_R32","first-page":"1066","article-title":"Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism.","volume":"86","author":"Magill","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616144321800_R33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00045415-199907000-00012","article-title":"Primary aldosteronism: a common and curable form of hypertension.","volume":"7","author":"Young Jr","year":"1999","journal-title":"Cardiol Rev"},{"key":"2020071616144321800_R34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3317\/jraas.2001.022","article-title":"Diagnosis and management of primary aldosteronism.","volume":"2","author":"Stowasser","year":"2001","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2020071616144321800_R35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s003450050099","article-title":"Diagnosis and treatment of primary aldosteronism.","volume":"17","author":"Blumenfeld","year":"1999","journal-title":"World J Urol"},{"key":"2020071616144321800_R36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archsurg.1996.01430180072015","article-title":"Factors influencing outcome of surgery for primary aldosteronism.","volume":"131","author":"Celen","year":"1996","journal-title":"Arch Surg"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/3\/1045\/10742192\/jcem1045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/89\/3\/1045\/10742192\/jcem1045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:12:24Z","timestamp":1594941144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/89\/3\/1045\/2844051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2003-031337","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}